# Kisspeptin FAQ: Questions on Mechanism, Dosage, Safety, and Research Applications > Kisspeptin questions answered from the published literature — mechanism, isoforms, half-life, fertility, testosterone, receptor desensitization, and regulatory status cited. ## Frequently Asked Questions about Kisspeptin Every answer below is drawn from the peer-reviewed research summarized on this site. ## What is kisspeptin? A neuropeptide family encoded by the KISS1 gene; binds the KISS1R (GPR54) receptor on hypothalamic GnRH neurons and is the principal upstream switch of the reproductive hormone axis. The precursor is a 145-amino-acid protein cleaved to produce KP-54, KP-14, KP-13, and KP-10. All isoforms share a C-terminal RF-amide motif required for receptor binding. [1] ## Does kisspeptin raise testosterone? In published research, yes — via an indirect upstream mechanism. IV kisspeptin-10 infusion raised mean LH from 5.2 to 14.1 IU/L and elevated testosterone in healthy men (George 2011, JCEM). [5] Kisspeptin acts at the hypothalamus; its testosterone effect depends on intact GnRH, LH, and testicular function. ## What is the half-life of kisspeptin? KP-10: approximately 4 minutes in humans (3.8 ± 0.3 min in men, 4.1 ± 0.4 min in women). KP-54: approximately 27–32 minutes in humans. [12] ## Is kisspeptin FDA approved? No. Kisspeptin remains an investigational peptide; no formulation has received FDA approval for any clinical indication as of 2025. [22] ## Can kisspeptin help with fertility? KP-54 was studied as an IVF oocyte maturation trigger with positive outcomes: 95% oocyte maturation, 62% live birth rate, zero OHSS at the optimal dose. [9] No formulation is approved for clinical fertility treatment. ## Does kisspeptin trigger ovulation? By driving an endogenous LH surge, yes — in the IVF context. Kisspeptin drives ovulation via an endogenous LH surge rather than by directly stimulating ovarian receptors. Zero OHSS cases and a 62% live birth rate were documented in the Phase 2 RCT. [9] ## What happens if you take too much kisspeptin? Continuous high-dose infusion produced receptor desensitization and paradoxical LH suppression. Twice-daily SC injections for 14 days caused the LH response to fall from ~24 IU/L to ~2.5 IU/L. [8] No serious adverse events were reported at any dose studied. [22] ## What is the difference between kisspeptin-10 and kisspeptin-54? Both activate KISS1R fully. KP-10: 10 AA, ~4 min half-life, cleared within 30 min of IV bolus. KP-54: 54 AA, ~27-32 min half-life, longer LH-stimulation window, used for IVF triggering and hypothalamic amenorrhea protocols. [12] ## What receptor does kisspeptin bind? Kisspeptin binds KISS1R (formerly GPR54), a Gq/11-coupled GPCR. Loss-of-function mutations cause hypogonadotropic hypogonadism; gain-of-function mutations cause central precocious puberty. [1][2] ## References [1] Seminara SB, et al. The GPR54 Gene as a Regulator of Puberty. NEJM. 2003. https://www.nejm.org/doi/full/10.1056/NEJMoa035322 [2] Teles MG, et al. A GPR54-Activating Mutation in a Patient with Central Precocious Puberty. NEJM. 2008. https://pubmed.ncbi.nlm.nih.gov/18272894/ [5] George JT, et al. Kisspeptin-10 is a potent stimulator of LH in men. JCEM. 2011. https://pubmed.ncbi.nlm.nih.gov/21632807/ [8] Jayasena CN, et al. Subcutaneous kisspeptin-54 causes tachyphylaxis. JCEM. 2009. https://pubmed.ncbi.nlm.nih.gov/19820030/ [9] Abbara A, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation. JCEM. 2015. https://pubmed.ncbi.nlm.nih.gov/26192876/ [12] d'Anglemont de Tassigny X, et al. Mechanistic insights into KP-54 vs KP-10. PLoS One. 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5413024/ [22] Velmurugan H, et al. Kisspeptin and its Current Clinical Status. Current Medicinal Chemistry. 2025. https://pubmed.ncbi.nlm.nih.gov/38265397/ --- The KISS1 record — mechanism, isoforms, and clinical trials — indexed here. Not a clinic, not a vendor.